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Abstract
It is important to identify patients with Maturity-onset diabetes of the young (MODY) as a molecular diagnosis determines
both treatment and prognosis. Genetic testing is currently expensive and many patients are therefore not assessed and are
misclassified as having either type 1 or type 2 diabetes. Biomarkers could facilitate the prioritisation of patients for genetic
testing. We hypothesised that patients with different underlying genetic aetiologies for their diabetes could have distinct
metabolic profiles which may uncover novel biomarkers. The aim of this study was to perform metabolic profiling in urine
from patients with MODY due to mutations in the genes encoding glucokinase (GCK) or hepatocyte nuclear factor 1 alpha
(HNF1A), type 2 diabetes (T2D) and normoglycaemic control subjects. Urinary metabolic profiling by Nuclear Magnetic
Resonance (NMR) and ultra performance liquid chromatography hyphenated to Q-TOF mass spectrometry (UPLC-MS) was
performed in a Discovery set of subjects with HNF1A-MODY (n = 14), GCK-MODY (n = 17), T2D (n = 14) and normoglycaemic
controls (n = 34). Data were used to build a valid partial least squares discriminate analysis (PLS-DA) model where HNF1A-
MODY subjects could be separated from the other diabetes subtypes. No single metabolite contributed significantly to the
separation of the patient groups. However, betaine, valine, glycine and glucose were elevated in the urine of HNF1A-MODY
subjects compared to the other subgroups. Direct measurements of urinary amino acids and betaine in an extended dataset
did not support differences between patients groups. Elevated urinary glucose in HNF1A-MODY is consistent with the
previously reported low renal threshold for glucose in this genetic subtype. In conclusion, we report the first metabolic
profiling study in monogenic diabetes and show that, despite the distinct biochemical pathways affected, there are unlikely
to be robust urinary biomarkers which distinguish monogenic subtypes from T2D. Our results have implications for studies
investigating metabolic profiles in complex traits including T2D.
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Introduction
Monogenic disorders of beta-cell function (maturity-onset
diabetes of the young; MODY) have a minimum estimated
prevalence of approximately 100 cases per million population
[1,2]. There are significant clinical implications for both patients
and their relatives associated with finding a genetic aetiology
underlying their diabetes and it is therefore important to identify
these individuals [3,4]. Diagnostic molecular testing is widely
available, however inequality in referral rates mean that a
significant proportion (.80%) of cases go undiagnosed and are
therefore misclassified as either type 1 (T1D) or type 2 diabetes
(T2D) [2]. The principle barriers to genetic testing include the cost
of DNA sequencing which prohibits indiscriminate use. Current
recommendations for genetic testing [5] are based on non-specific
clinical criteria such as age of onset of diabetes, family history and
an atypical clinical presentation for either T1D or T2D which
have a high specificity but low sensitivity [6]. Robust cost-effective
biomarkers which could be used as an adjunct to current tests to
prioritise patients for molecular genetic testing could help address
this problem.
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The most common subtypes of MODY in all populations studied
are the result of mutations in the genes encoding the transcription
factor Hepatocyte nuclear factor 1 alpha (HNF1A) and the key
glycolytic enzyme glucokinase (GCK) [5]. HNF1A is expressed in a
number of tissues including pancreas and liver where it plays an
important role in the regulation of a large number of genes [7]. It is
the role of HNF1A in liver which provides the greatest potential for
urinary and/or plasma biomarkers, which could aid the differen-
tiation from other forms of diabetes.
There have been several studies evaluating candidate biomark-
ers which have emerged from rodent models and human genetics
but until recently none have demonstrated sufficient specificity and
sensitivity and/or withstood replication in other populations
[8,9,10,11,12,13,14,15,16]. The most promising biomarker to
date is highly sensitive C-reactive protein (hsCRP) [6,11,17].
Although these data are promising, one significant limitation of
CRP as a biomarker is that it is an acute phase protein and levels
are raised during infection [11]. Metabolomics aims/endeavours
to provide a global assessment of metabolites in a given sample
and has recently been used to investigate Hnf1a1-dependent
pathways in urine samples from Hnf1a2/2 null and wild-type mice
[18]. More recently, metabolic profiling has been proposed as a
platform for identifying metabolites which serve as accurate
indicators of diabetes pathogenesis and progression [19,20]. Given
the different genetic aetiologies and distinct metabolic pathways
affected, we hypothesised that subjects with HNF1A-MODY
could have a different pattern of urinary metabolic profile
compared to subjects with GCK-MODY and T2D. The first
aim of this study was to determine the metabolic profiles of
subjects with monogenic diabetes and identify metabolites which
distinguish the different genetic subtypes (Discovery Study) and
second to evaluate potential biomarkers in an extended group of
subjects.
Results
Metabolic profiling of diabetic subtypes by Ultra
Performance Liquid Chromatography Mass Spectrometry
(UPLC-MS)
We compared the metabolic urine profile of samples from
normoglycaemic control and T2D subjects with samples from
HNF1A-MODY and GCK-MODY subjects. The clinical char-
acteristics of the subjects studied are given in table 1. Urine
samples were analysed using two different platforms; liquid
chromatography mass spectrometry (LC-MS) and 1H nuclear
magnetic resonance spectroscopy (NMR).
The LC-MS based method acquired approximately 3000 MS
peaks of positive ions (ESI+). Representative positive base peak
intensity (TBPI) chromatograms of the controls and the three
diabetic subgroups are shown in Figure S1. Maximum separation
between the four defined classes in the data (controls, T2D,
HNF1A-MODY and GCK-MODY) was assessed using partial
least squares regression discriminant analysis (PLS-DA) models.
The models were built from 1752 peaks of normalized MS data
after eliminating the background and non-biologically relevant
peaks. A four-class model of controls versus the three diabetic
subgroups as separate classes showed a reasonable separation
between the controls and the three diabetic groups, but the model
was not valid in a permutation test (Table S1). A two-class model
of the controls versus all diabetic subjects as one group proved to
be valid with a Q2 above 0.5 (Table S1 and Figure S2). Three
non-diabetic HNF1Amutation carriers and a mutation carrier with
impaired glucose tolerance (IGT) were included with the HNF1A
subjects selected for the Discovery study. These four subjects were
first predicted into the two-class model, but since they all grouped
with the diabetic subjects in the model, these four samples were
included in HNF1A-MODY group in all subsequent analyses (red
and blue boxes in Figure S2).
We then tested if the metabolic profiles of the MODY subtypes,
HNF1A-MODY and GCK-MODY, were different from T2D
subjects in a three-class PLS-DA model. The model with low Q2
proved to be non-valid in a permutation test (Table S1). However,
the HNF1A-MODY group was well separated from the two other
groups in the score plot (Figure S3), and consequently a two-class
model was built having merged the GCK-MODY and T2D groups.
This model tested valid with Q2 above 0.5 using three components
(Figure 1, Table S1). We examined the models for possible
confounding effects from age, gender, BMI and family membership
on the class prediction, but the valid models did not show any
separation trends between the classes based on these factors.
In an attempt to look for interesting MS peak variables that
contributed to the separation of the HNF1A-MODY group from
the merged GCK-MODY and diet treated T2D groups, the S-plot
from a two-class O-PLS-DA model (data not shown) was
examined. Some of the MS peaks were singled out as the most
important contributors to the HNF1A-MODY class separation.
However, looking at the MS raw data it appeared the selected
peaks had very high intensity levels in several of the HNF1A-
MODY subjects, but their levels were at the level of the controls
and the other diabetic groups in the rest of the HNF1A-MODY
subjects (Figure 2). Thus, the clear separation of HNF1A-MODY
subgroup from the other diabetic subgroups in the two-class model
could not reveal any significant individual metabolic markers
across the entire subgroup.
The two peaks with the highest contributions to the HNF1A-
MODY subgroup separation were chosen for closer examination,
and the corresponding metabolites were confirmed by comparison
of accurate mass, retention time, co-elution, and MS/MS mass
spectra to those of authentic standards. They were betaine (m/z
118.086), ESI+) and glucose (m/z 219.016, ESI+) (Figure 2). The
high betaine and glucose levels were not directly correlated with
each other in more than two subjects (Figure S4). The high
glucose and betaine levels did not show any strong correlations
when plotted against the clinical parameters measured (HbA1c,
fasting blood glucose, BMI or duration of disease). There was
however a correlation between betaine levels and gender. A plot of
betaine peak intensity levels for the three diabetic subgroups
showed that the HNF1A-MODY subjects with abnormal betaine
levels were all female (Figure S5). However, this observation could
be a coincidence considering the low number of subjects in the
HNF1A-MODY group (n= 24), a majority of whom were female.
The four non-diabetic HNF1A-MODY mutation carriers had
some of the lowest betaine levels observed in this study, and when
betaine levels were plotted against fasting plasma glucose levels for
all HNF1A-MODY subjects, the four mutation carriers clustered
together (Figure S6).
Metabolic profiling of diabetic subjects by 1H nuclear
magnetic resonance spectroscopy (NMR)
Similar to the modelling process of MS data, multivariate
models were acquired for NMR data. The glucose regions of the
NMR spectra had to be removed due to very high urine glucose
levels in several of the HNF1A-MODY subjects. The processed
NMR spectra were modelled with PLS-DA to discriminate the
diabetic subgroups (Figure S7). The PLS-DA model showed
reasonable separation of the three diabetic subgroups, but the
model was not valid (Q2= 0.06). In addition, the model was not
improved when T2D and GCK-MODY groups were merged into
Metabolic Profiling in MODY
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one class of a two-class model. Examination of the loading plot of
the PLS-DA model (data not shown) identified the NMR markers
that contributed to the separation of HNF1A-MODY subjects
from the other diabetic subgroups mainly as amino acids.
The changes in amino acids were then examined more closely
using targeted profiling of the NMR spectra to obtain relative
quantification of alanine, glycine, histidine, lysine, methionine,
phenylalanine, threonine, tryptophan, tyrosine and valine. The
HNF1A-MODY subjects showed significant increase in valine
compared to GCK-MODY and T2D subjects, significant decrease
in threonine compared to GCK-MODY subjects and significant
increase in glycine compared to T2D subjects (Table S2).
Validation of Signals found in Discovery Study
Urinary Glucose Analysis. Urinary glucose was measured
in subjects with HNF1A-MODY, GCK-MODY and T2D.
Results are shown in Table 2. Given that subjects with HNF1A-
Table 1. Clinical Characteristics of Subjects in the Discovery and extended datasets.
Discovery dataset Extended dataset
HNF1A-MODY
n=25
GCK-MODY
n=24
T2D
n=14
Non-diabetic
n=34
HNF1A-MODY
n=39
T2D
n=158
Gender M:F % 36:64 42:58 50:50 53:47 33:67 57:43
Age at sampling years 38.3(26.9) 25.1(11.4) 52.7(12.1) 49(8.5) 44.2(24.0) 52.4(18.2)
Duration of diabetes
years
11.9(24.9)
4 subjects
non-diabetic
Hyperglycaemia from
birth
3.8(3.5) N/A 21.5(29.1)
6 subjects
non-diabetic
14.8(16.9)
Treatment
Diet:OHA:Insulin %
14:43:38 79:21:0 100:0:0 N/A 10:43:47 3:29:68
Fasting glucose mmolL21 8.3(3.4) 7.1(1.1) 6.3(2.4) 5.1(0.4) 6.9 (4.1) 8.5(3.8)
HbA1c % 7 (1.4) 6.5(0.7) 6.1(0.7) Not available 7.1(1.4) 7.6(2.0)
BMI kgm22 24.3(4.1) 25.1(11.4) 31.4(8.5) 24.7(3.4) 24.2(4.7) 33.1(9.4)
Data is shown as median (IQR) or %.
doi:10.1371/journal.pone.0040962.t001
Figure 1. 3D score plot of a two-class PLS-DA model of HNF1A
versus T2D/GCK; green triangle = HNF1A, red triangle = GCK
and blue triangle = T2D. Q2= 0.518 using three PLS-components in
a valid model (Q2Y = 0.52).
doi:10.1371/journal.pone.0040962.g001
Figure 2. Scatter diagrams of betaine (A) and glucose adduct
(B) ESI+-MS peak intensities in detected samples; grey triangle
= control, green triangle = HNF1A, red triangle = GCK and
blue triangle = T2D. Intensity of the signal is plotted as a constant
sum normalized value.
doi:10.1371/journal.pone.0040962.g002
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MODY are known to have a low renal threshold for glucose, we
calculated both urinary glucose/creatinine (UG/Cr) ratio and
plasma glucose to urinary glucose/creatinine ratio PG/(UG/Cr).
These measures showed a significant difference across the three
groups, with the least urinary glucose found in those with GCK-
MODY and the most in those with HNF1A-MODY. Similarly the
largest PG/(UG/Cr) ratio was found in those with GCK-MODY
and the lowest with HNF1A-MODY. Subjects with T2D had
intermediate values. This is in keeping with previous observations
of serum 1,5AG levels, which are correlated with urine glucose
levels [12].
We then examined whether UG/Cr or PG/(UG/Cr) could be
used to discriminate HNF1A-MODY from young-onset T2D using
Receiver Operating Characteristic (ROC) Curve analysis. The area
under the ROC curve for both these two parameters was ,0.6,
showing that features based on urine glucose do not provide
clinically useful discrimination between HNF1A-MODY and T2D.
Urinary Amino Acid Analysis. Once matched for urinary
glucose levels, there was no difference observed in the levels of the
urinary amino acids valine and glycine, which were noted in the
Discovery study to be increased in HNF1A-MODY subjects
(Table 2).
Urinary Betaine Analysis. Betaine/Cr ratio was noted to be
high in the urine of HNF1A-MODY subjects in the Discovery
Study compared to Diet-controlled T2D and GCK-MODY. On
quantifying the extended dataset, however, the opposite finding
was noted with markedly higher betaine noted in the T2D group.
Two close metabolites of betaine were also higher in the T2D
group: Choline, which is a precursor of betaine, and sarcosine, a
product of betaine demethylation. Urinary betaine/Cr levels were
correlated with fasting glucose (p = 261025), urine glucose
(p = 3.561024) and HbA1c (161024). Linear regression showed
that the significant determinants of urinary betaine/Cr were
urinary glucose (p = 0.021) and type of diabetes (p = 0.038). After
controlling for urinary glucose levels, fasting glucose and HbA1c
did not significantly affect betaine/Cr ratio.
Biomarkers in combination with clinical features. It is
likely that combinations of clinical features and biomarkers will be
used in clinical algorithms to identify those at high risk of MODY.
Linear regression modelling in the HNF1A-MODY and T2D
cases from the extended dataset showed that (young) age of onset
of diabetes was the most important predictor of HNF1A-MODY
(P,0.001), with urinary glucose/Cr ratio having a more modest
effect (p = 0.03).
Discussion
We designed this study to try to identify urinary markers which
might be useful in the clinical discrimination of diabetes subtypes
in young adults; a group in whom many are missing the
opportunities offered by accurate molecular diagnosis. This study
has the advantage of a biology agnostic design to identify
metabolic markers associated with monogenic subtypes without
making prior assumptions about candidacy.
PLS-DA models were used explore the metabolic discrimination
between normoglycaemic controls and the various diabetic
subtypes. The models showed that compared to the normogly-
caemic controls all the diabetic subjects were metabolically
‘similar’ and had to be treated as one class to make a valid
discrimination model against the controls. The four non-diabetic
HNF1A mutation carriers showed more features of the diabetic
subjects than the normoglycaemic controls despite their fasting
blood glucose and HbA1c values being within the normal range.
This is in agreement with previous studies on non-diabetic HNF1A
mutation carriers which demonstrated that many aspects of the
HNF1A-MODY diabetic phenotype, such as b-cell deficiency and
low renal threshold for glucose, are already present in the
mutation carriers before the development of frank diabetes [21].
The diabetic subtype discrimination model showed that the
HNF1A metabolic profile differs sufficiently from the other two
subtypes to make a valid model. However, the attempt to classify
GCK and T2D separately failed. This probably reflects that the
diet-controlled T2D subjects used in the discovery part of the
study were metabolically closer to the GCK-MODY subjects than
a more typical T2D subject (and this may be a limitation of the
design of this study in terms of finding markers that discriminate
T2D and GCK-MODY).
Table 2. Follow up of glucose, amino acid and betaine signals.
HNF1A-MODY GCK-MODY T2D p
C statistic
HNF1A vs T2D
Urine Glucose n= 27 n = 17 n = 158
Urinary glucose/Cr ratio (mmol/mmol) 0.67(1.84) 0.039(0.024) 0.13(1.88) *0.01 0.58
Plasma glucose/Urinary glucose ratio
(mmol/mmol)
0.73(5.87) 12.41(9.47) 6.92(19.14) *0.04 0.63
Plasma glucose/(Urinary glucose/
creatinine ratio) mmol/ (mmol/mmol)
13.1 (138.3) 178. 9 (100.3) 72.0 (174.7) *0.01 0.55
Amino Acids n= 22 n = 22-
Valine/Cr ratio (mmol/mmol) 0.35 (0.62) 0.67 (0.92) 0.08
Alanine/Cr ratio (mmol/mmol) 2.00 (3.80) 4.79 (4.61) 0.18
One-Carbon compounds n= 39 N= 80
Glycine/Cr ratio (mmol/mmol) 93.6 (73.6) 88.1 (68.0) 0.87
Urinary betaine/Cr ratio (mmol/mmol) 19.5 (28.2) 34.9 (52.9) ,0.001 0.70
Sarcosine/Cr ratio (mmol/mmol) 0.21 (0.25) 0.27 (0.24) 0.03 0.63
Choline/Cr ratio (mmol/mmol) 2.75 (2.59) 4.00 (3.43) 0.003 0.67
Data are median (IQR). P values compare HNF1A and T2D using Mann Whitney U test except for * where comparisons between all 3 groups are calculated by Kruskal-
Wallis test.
doi:10.1371/journal.pone.0040962.t002
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Using the UPLC-MS methodology, we identified two peaks that
were associated with HNF1A-MODY cases rather than T2D and
GCK-MODY subjects. Firstly they had increased urinary glucose
levels. This was not surprising as low renal threshold is seen
clinically in this form of diabetes and attributed to reduced
expression of the low affinity/high-capacity glucose co-transporter
(SGLT2) which is regulated by HNF1A [22]. In this study we have
examined for the first time whether parameters derived directly
from urinary glucose measurement can be used as a simple
diagnostic screen for HNF1A-MODY cases. Although a signifi-
cant difference is observed, this is not of high discriminative
accuracy as demonstrated by a ROC curve derived C-statistic of
,0.6.
The MS study also identified increased urinary betaine levels in
the HNF1A-MODY subjects. We were unable to confirm this in
the extended study – in fact we observed that betaine excretion
was significantly higher in individuals with T2D. Betaine is
important in mammalian physiology in two main ways [23]: firstly
it is involved in metabolism of one-carbon compounds by acting as
the donor of a methyl group in the conversion of homocysteine to
methionine and secondly it is one of the major osmolytes utilised in
the kidney and other tissues. Urinary betaine excretion is known to
be increased in diabetic individuals [24] and in those who have
metabolic syndrome [25].
The increased urinary betaine excretion seen in those with
metabolic syndrome means we would expect that subjects with
T2D would have higher urine betaine as we saw in the extended
study. The initial observation was thus likely to be spurious and
due to differences in the T2D groups used in the two arms of the
study. The diet-controlled T2D subjects selected for the discovery
part of the study had lower fasting glucose and HbA1c levels than
the more typical T2D group used in the extended study (both
p,0.03 between discovery and extended study groups). Betaine
excretion has been previously reported to be correlated with
fasting glucose levels [24] and from our results appears to be partly
driven by glycosuria (which is itself correlated with fasting glucose
and HbA1c). This might be expected to increase betaine excretion
in subjects such as the HNF1A-MODY cases who have a low renal
threshold for glucose. Interestingly our observation that urine
glucose excretion is correlated with urinary betaine has recently
been reported by another group [26], the mechanisms of this
warrant further investigation.
Alterations in serum and urinary amino acids are seen in the
Hnf1a2/2 mouse and have been investigated previously as
candidate biomarkers for HNF1A-MODY [8,16]. In the study by
Bingham et al [8], aminoaciduria was seen in other forms of
diabetes as well as HNF1A-MODY and was thought to be driven
by the presence of glycosuria. We matched for urine glucose in
order to establish definitively whether there were any differences in
urinary amino acids between T2D and HNF1A-MODY that were
additional to the effects of glycosuria. No differences were seen and
thus we conclude that urinary amino acid profile cannot be used as
a marker for HNF1A-MODY.
In conclusion, the overall findings of this study were that there
were no robust differences found on metabolic profiling of young-
adults with different diabetes subtypes that would aid clinical
discrimination of these subtypes and identify those in whom
genetic testing might be beneficial. We did however confirm the
expected difference of increased urinary glucose in HNF1A-
MODY highlighting that the numbers of cases included and the
study design was adequate to identify differences between the
subgroups. However, the T2D group, selected because they were
diet controlled and thus on few medications and without
complications of diabetes, was too metabolically similar to the
GCK–MODY group to allow good separation.
Our study has implications for metabolic profiling in complex
metabolic disorders such as T2D, as despite using homogenous
subgroups with different underlying pathophysiologies, we have
failed to detect urinary metabolic differences which translate into
robust biomarkers. Alternative omic approaches such as peptide or
protemomics might be more effective in identifying robust
biomarkers for diabetes subtype discrimination.
Materials and Methods
Ethics Statement
The study was performed according to the latest version of the
Helsinki Declaration. Ethical approval was obtained from the
Oxfordshire local research ethics committee and all subjects gave
written informed consent prior to participation.
Subjects
For the initial Discovery study we included 14 cases of HNF1A-
MODY, 17 of GCK-MODY, 14 cases of diet controlled young-
onset T2D (diagnosed up to 45 years of age) and 34 non-diabetic
individuals (Table 1). Due to the lower prevalence of HNF4A-
MODY compared with GCK and HNF1A-MODY we were
unable to recruit individuals with HNF4A mutations for this study
[2]. Subjects for the extended study were selected from a larger
pool of subjects as detailed below. The T2D subjects used in the
extended study were independent of those used in the Discovery
study, and represented a more typical mixture of T2D cases
(longer duration, treated with diet, oral agents or insulin). The
HNF1A-MODY cases in the extended study included as a subset
those who took part in the Discovery study.
Subjects were ascertained from Oxfordshire, UK and those with
MODY from Oxfordshire and other counties in the South of
England. The MODY subjects comprised subjects with known
pathogenic mutation (confirmed by sequencing in a certified UK
diagnostic centre) in either HNF1A or GCK. The individuals with
MODY were recruited from patients known to our clinical service,
family members of those patients or patients from other hospitals
identified by the Genetic Diabetes Nurse network. One HNF1A-
MODY had impaired glucose tolerance (IGT) and 3 were
normoglycaemic; the remainder had diabetes. Oral glucose
tolerance test (OGTT) data at the time of sampling were available
on the non-diabetic HNF1A-MODY mutation carriers to confirm
diabetic status. Subjects with GCK mutations are affected with
lifelong fasting hyperglycaemia.
The T2D subjects were selected from the Young Diabetes in
Oxford study, comprising subjects diagnosed with diabetes
#45 years of age, C-peptide positive and with negative GAD
antibodies. Individuals selected for the Discovery study were all
diet treated, while those in the extended study were on various
treatments (see Table 1). Subjects did not meet clinical criteria for
MODY diagnostic testing [5] or had been tested and were
negative for mutations in HNF1A/HNF4A and/or GCK.
Non-diabetic subjects (ND, n= 34) in the Discovery study were
recruited from the Oxford Biobank (http://www.oxfordbrc.org/
research/chronic-disease-cohorts/102/), a population-based col-
lection of healthy adults aged 30–50 recruited for translational
medicine studies. Normoglycaemia was defined as fasting glucose
,6.0 mmol/l and no history of a diagnosis of diabetes. All subjects
were of European ethnicity.
Metabolic Profiling in MODY
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Sample Collection and Preparation
An early morning urine sample was supplied by each subject.
The urine was centrifuged and the supernatant separated and
stored at280uC. Analysis of urinary glucose and creatinine as well
as a paired sample for fasting plasma glucose, HbA1c and serum
creatinine was performed in the Department of Biochemistry at
the John Radcliffe Hospital, Oxford using standard analysis
methods. The samples were prepared for UPLC-MS and NMR
analyses according to sampling procedure in the supplementary
online methods (Text S1).
UPLC-MS
The UPLC Q-Tof MS system comprised an AQUITY UPLC
hyphenated to a Q-TOF Premier mass spectrometer (Waters,
Milford, USA) (for details see supplementary online methods,
Text S1). The identification process of important metabolites was
performed by accurate mass and MS/MS measurements and
confirmed by co-elution with commercially purchased standards.
1H NMR spectroscopy
One-dimensional 1H NMR spectra were acquired on a Bruker
DRX 600 spectrometer (Bruker BioSpin, Rheinstetten, Germany)
(for details see supplementary online methods, Text S1). Assign-
ments of metabolites were based on literature values. The targeted
profiling approach in the Chenomx NMR Suite v7.0 (Chenomx
Inc., Alberta, Canada) was used to relatively quantify amino acids.
Data processing
Control urine samples were used to check the reproducibility of
MS and NMR data acquisition across well plates. MassLynx v4.0
(Waters, Milford, USA) was used to convert the centroid UPLC-
MS data files to NetCDF format for further processing. XCMS
[27] software was used for peak matching, non-linear retention
time alignment and quantitation of mass spectral ion intensities
across all NetCDF mass spectral files. The method is described in
detail in the Supplementary online methods. Normalised data sets
were constructed using constant sum normalisation. The NMR
spectra were phase and baseline corrected and chemical shift
aligned to the internal standard. Spectral regions corresponding to
water were removed. Glucose regions were also removed due to
high urine glucose levels in many of the HNF1A-MODY samples.
The full resolution NMR spectra were normalized using proba-
bilistic quotient normalisation [28].
Data analysis
The MS peaks present in blank water samples were removed
across all spectra, and all models were calculated with univariate
scaled data. All NMR models used Pareto scaled data. Principal
component analysis (PCA) of the MS and NMR data was used to
check for outliers and trends due to gender, age, and family.
Partial least squares discriminant analysis (PLS-DA) was used to
model the discrimination between the HNF1A, GCK, T2D and
ND groups. Cross-validation with seven cross-validation groups
was used to determine the number of components. The validity of
the PLS-DA models was assessed using a response permutation
test with 200 permutations, and Q2.0.5 was considered to be a
good model. O-PLS-DA model S-plot [29] was used to look for
MS peaks that might contribute significantly to the separation of
the diabetic subclasses.
Individual urine amino acids determined by 1H NMR
spectroscopy were compared across the groups of diabetic
individuals by unpaired t-tests.
Quantification of urinary Valine and Glycine
A subset of 22 HNF1A-MODY and 22 T2D subjects were
selected for analysis. Samples were matched for urine glucose, to
control for the known effect of glycosuria as a cause of
aminoaciduria [8]. Analysis was performed in the Biochemistry
lab at the John Radcliffe Hospital, Oxford. Samples for amino
acid analysis underwent pre-column derivatisation using Ac-
cQ?Fluor reagent (Waters, Milford, USA). Briefly, internals
standards (methylphenylalanine and methionine sulfone, Sigma)
were added to each specimen. Proteins were precipitated by the
addition of acetonitrile and isolated by centrifugation. Superna-
tants were subsequently derivatised using AccQ?Fluor reagent.
Amino acid derivatives were separated on a Waters ACQUITY
UPLC system (Waters, Milford, USA) with UV absorbance
measured at 260 nm. Gradient chromatography was employed
using AccQ?Tag Ultra mobile phases (AccQ?Tag Ultra eluent A
and AccQ?Tag Ultra eluent B), flow rate of 0.6 ml/min, injection
volume of 1 ml, ACQUITY UPLC BEH C18 column (1.7 mm
2.16150 mm), column temperature of 60uC. Calibration was
performed using an amino acid standard solution (Sigma) and
analyses were verified using in-house quality control material.
Data analysis was performed using Empower 2 software (Waters,
Milford, USA).
Quantification of betaine, related methylamines and
selected amino acids
Thirty-nine HNF1A-MODY and 80 T2D subjects were selected
for analysis. Samples were analysed by Bevital laboratories, Bergen,
Norway using high-throughput systems [23]. Betaine and a number
of close metabolites in the one-carbon pathway were selected for
analysis: total homocysteine, methylmalonic acid, cysteine, methio-
nine, serine, glycine, cystathionine, kynurenine (analysed by gas
chromatography/mass spectrometry); sarcosine and tryptophan (gas
chromatography/tandem mass spectrometry) and choline, betaine,
dimethylglycine, arginine and asymmetric/symmetric dimethylargi-
nine (by liquid chromatography/tandem mass spectrometry).
Statistical Analysis for the amino acid and one-carbon
validations
Differences between medians were calculated using Mann
Whitney U or Kruskal Wallis tests. Statistical analysis was
performed in SPSS v18 and p,0.05 was considered significant.
Supporting Information
Figure S1 Typical base peak MS chromatograms ob-
tained from urine of: A) T2D; B) GCK; C) HNF1A and D)
healthy controls, scanned by ESI+.
(TIF)
Figure S2 Score plot of a 2-class PLS-DA model of the
control group versus the three diabetic subgroups
together; Grey triangle = control, green triangle =
HNF1A, red triangle = GCK and blue triangle = T2D.
Q2=0.55 using two PLS components in a valid model. The
samples in red boxes are three HNF1A non-diabetic mutation
carriers; the blue box sample is a HNF1A IGT mutation carrier.
(TIF)
Figure S3 Score plot of a three-class PLS-DA model of
the three diabetic subgroups using ESI+-MS data.
Q2=0.011 for the first two components in a non-valid model.
Grey triangle = control, green triangle = HNF1A, red triangle
= GCK and blue triangle = T2D.
(TIF)
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Figure S4 Plot of betaine versus glucose ESI+-MS peak
intensities from all diabetic subjects. Intensity of the signal
is plotted as a constant sum normalized value. Grey triangle =
control, green triangle = HNF1A, red triangle = GCK and blue
triangle = T2D. Regression coefficient (R2) = 0.1662.
(TIF)
Figure S5 Profile of betaine excretion from ESI+-MS
data stratified by diabetes subtype and gender. Intensity
of the signal is plotted as a constant sum normalized value
(diamond: male; red cross: female).
(TIF)
Figure S6 Plot of betaine ESI+-MS peak intensity versus
measured fasting glucose levels of all HNF1A-MODY
subjects. The samples in red boxes are three non-diabetic
HNF1A mutation carriers; the blue box sample is an HNF1A
mutation carrier with impaired glucose tolerance.
(TIF)
Figure S7 Score plot of a three-class PLS-DA model of
the three diabetic subgroups using NMR data. Q2=0.06
for the first two components in a non-valid model. Grey triangle
= control, green triangle = HNF1A, red triangle = GCK and
blue triangle = T2D.
(TIF)
Text S1 Online supplementary methods.
(DOC)
Table S1 Q2Y (goodness of fit) for PLS-DA models.
(DOC)
Table S2 Amino acid concentrations in urine measured
by 1H NMR in the diabetic subgroups.
(DOC)
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